Lilly says oral GLP-1 Foundayo beats oral semaglutide in Phase 3 ACHIEVE-3 diabetes trial

Eli Lilly

LLY

0.00

Eli Lilly disclosed Phase 3 ACHIEVE program results for oral GLP-1 Foundayo in type 2 diabetes, already presented at the ADA 86th Scientific Sessions.
The head-to-head ACHIEVE-3 trial showed Foundayo delivered stronger blood sugar control and greater weight loss than oral semaglutide.
Two additional pivotal studies showed Foundayo improved blood sugar control and supported weight reduction versus dapagliflozin or placebo when added to insulin.
Lilly plans to file Foundayo for a type 2 diabetes indication with the US FDA by the end of the second quarter, setting up a potential label expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606081430PR_NEWS_USPR_____DE77168) on June 08, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.